The overall 5-year relative survival rate for melanoma is 94.7%, making it one of the more survivable cancers when all stages are combined. That number, drawn from cases diagnosed between 2016 and 2022, reflects the fact that most melanomas are caught early. But survival varies dramatically by stage, and recent advances in treatment have reshaped the outlook even for advanced cases.
Survival Rates by Stage at Diagnosis
Stage at diagnosis is the single biggest factor in melanoma survival. The numbers break down into three broad categories based on how far the cancer has spread:
- Localized (confined to the skin): 100% 5-year relative survival. About 77% of melanomas are diagnosed at this stage.
- Regional (spread to nearby lymph nodes): 76% 5-year relative survival. Around 10% of cases fall here.
- Distant (metastasized to other organs): 34% 5-year relative survival. This accounts for about 5% of diagnoses.
These figures use a simplified staging system. The more detailed clinical staging system (stages 0 through IV) shows a steeper drop: stages I and II have a 97.6% 5-year survival rate, stage III drops to 60.3%, and stage IV falls to 16.2%. The gap between the two sets of numbers reflects differences in how the staging systems group patients and the time periods the data were collected.
How Tumor Thickness Affects Outcomes
For early-stage melanoma, the depth of the tumor in the skin is one of the strongest predictors of long-term survival. Tumors thinner than 0.8 millimeters carry a 20-year survival rate of 94.2%. Once thickness crosses that 0.8 mm line, even slightly (between 0.8 and 1.0 mm), the 20-year survival rate drops to 87.8%. That may not sound like a large gap, but the risk of dying from melanoma roughly triples for tumors in that higher-thickness group.
This is why dermatologists pay close attention to tumor depth when planning treatment. A fraction of a millimeter can shift a melanoma from very low risk to moderate risk, potentially changing whether additional procedures like sentinel lymph node biopsy are recommended.
Immunotherapy Has Changed Advanced Melanoma
The survival landscape for metastatic melanoma has shifted more than almost any other cancer in recent years. In 2011, the median survival for patients with metastatic melanoma was just six and a half months. Today, that number is over six years for patients treated with combination immunotherapy.
Long-term data from an international trial of 945 patients showed that roughly half of those treated with a combination of two immune checkpoint inhibitors survived cancer-free for 10 years or more. Patients who remained free of disease progression at the three-year mark had a high likelihood of staying alive and disease-free at 10 years. For a cancer that was once considered nearly universally fatal at the metastatic stage, this represents a fundamental change in prognosis.
These treatments work by releasing the brakes on the immune system, allowing it to recognize and attack melanoma cells. Not every patient responds, and the treatments can cause significant side effects. But for those who do respond, the results can be durable in a way that older treatments rarely achieved.
Recurrence Risk After Surgery
For stages 0 and I, surgery is typically curative, with a recurrence risk estimated at less than 2%. The picture changes as stage increases. Even stage IIIA, which involves lymph node spread, carries a recurrence risk below 20%, which is generally considered low enough that additional preventive treatment after surgery isn’t routinely recommended.
Higher-risk stage III patients face greater recurrence odds, which is why doctors may recommend post-surgical (adjuvant) therapy with immunotherapy or targeted treatments. The goal is to eliminate microscopic cancer cells that may remain after the primary tumor and affected lymph nodes are removed.
Gender and Age Differences
Women have a consistent survival advantage over men with melanoma, and the gap isn’t explained by earlier detection alone. After adjusting for tumor thickness, age, and other factors, women are about 38% less likely to die from melanoma than men. They’re also less likely to develop metastases in the first place: the risk of spread to lymph nodes is roughly 42% lower in women, and the risk of spread to distant organs is about 44% lower.
This female advantage holds even after the cancer has already spread to lymph nodes. It narrows only at the most advanced stage, when cancer has reached distant organs. Researchers believe the difference is biological rather than behavioral, though the exact mechanism isn’t fully understood. Men are also diagnosed at a slightly older age on average (median 58.5 years versus 55.9 for women), and older age at diagnosis is generally associated with worse outcomes across many cancers.
What These Numbers Mean for Individual Patients
Survival statistics describe populations, not individuals. A 76% 5-year survival rate for regional melanoma means that out of 100 people with that diagnosis, roughly 76 will be alive five years later. It doesn’t account for your specific tumor biology, your overall health, or which treatments you receive. The rapid improvements in immunotherapy mean that survival data from even five years ago may underestimate the outlook for someone diagnosed today.
The factors that matter most for your individual prognosis are stage at diagnosis, tumor thickness, whether the tumor is ulcerated (has a broken skin surface), and how well you respond to treatment if therapy beyond surgery is needed. For the vast majority of people diagnosed with melanoma, the odds are strongly in their favor.